

Product Information

Chondroitinase ABC from *Proteus vulgaris*

Lyophilized powder, 0.3-3 units/mg solid

C2905

Product Description

CAS Registry Number: 9024-13-9

Enzyme Commission (EC) Numbers:

- EC 4.2.2.20 (chondroitin-sulfate-ABC endolyase component)¹
- EC 4.2.2.21 (chondroitin-sulfate-ABC exolyase, component)¹

Synonym: Chondroitin ABC Lyase

pH optimum:²

- pH 8.0 (chondroitin sulfate)
- pH 6.8 (hyaluronic acid)

Temperature optimum:² 37 °CActivator:³ 0.05 M acetateInhibitor:³ 1 mM Zn²⁺

Chondroitinase ABC catalyzes the eliminative degradation of polysaccharides that contain (1→4)-β-D-hexosaminy and (1→3)-β-D-glucuronosyl or (1→3)-α-L-iduronosyl linkages to disaccharides containing 4-deoxy-β-D-gluc-4-enuronosyl groups. Chondroitinase ABC acts on chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate, and acts slowly on hyaluronate.⁴ Initial rates of degradation of chondroitin sulfate B, chondroitin, and hyaluronic acid were, respectively, 40%, 20%, and 2% those observed with chondroitin sulfate A and chondroitin sulfate C.²

The molecular mass of Chondroitinase ABC is ~120 kDa, as analyzed by gel filtration and sucrose gradient ultracentrifugation.²⁻⁴ SDS-PAGE indicates two non-identical subunits with molecular masses of ~86 kDa and ~32 kDa.^{3,5}

This product is purified from *Proteus vulgaris*. Several theses^{6,7} and dissertations⁸⁻¹⁸ have cited use of product C2905 in their protocols.

Reagent

The product is supplied as a lyophilized powder with 25-45% protein. Of the protein, the major component (~90% of the protein) is BSA (as a stabilizer). The balance of the overall powder (~65%) is Trizma® buffer salts.

Specific Activity: 0.3-3 units/mg protein (using chondroitin sulfate C as substrate)

Unit definition: One unit will liberate 1.0 μmole of a mixture of 2-acetamido-2-deoxy-3-O-(β-D-gluc-4-ene-pyranosyluronic acid)-4-O-sulfo-D-galactose and 1.0 μmole of 2-acetamido-2-deoxy-3-O-(β-D-gluc-4-ene-pyranosyluronic acid)-6-O-sulfo-D-galactose from chondroitin sulfate from shark cartilage, per minute at pH 8.0 at 37 °C.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Reconstitute in a 0.01% BSA aqueous solution. Further dilutions can be made into a buffer containing 50 mM Trizma® HCl, pH 8.0, with 60 mM sodium acetate and 0.02% BSA. Prepare solutions just prior to use. While we have not tested solution stability of this reagent, one publication reports storage of stock solutions of this product (2.5 units/mL, 4 units/mL), prepared in 20 mM HEPES-HBSS buffer, at -20 °C.¹⁹

Storage/Stability

Store the product desiccated at -20 °C and it is expected to remain active for at least 3 years.

References

1. Past EC Numbers include 4.2.2.4 and 4.2.99.6.
2. Yamagata, T. *et al.*, *J. Biol. Chem.*, **243(7)**, 1523-1535 (1968).

MERCK

3. Martinez, J.B. *et al.*, *J. Biol. Chem.*, **234(9)**, 2236-2239 (1959).
4. *Enzyme Nomenclature*, Academic Press (San Diego, CA), p. 425 (1992).
5. Sato, N. *et al.*, *Agr. Biol. Chem.*, **50(4)**, 1057-1059 (1986).
6. Henderson-Toth, Caitlin, "The formation of shear sensing mechanisms during embryonic vascular development: the role of the glycocalyx". McGill University, M.Sc.Eng. thesis, p. 27 (2011).
7. Saldanha, Ana Luísa Gonçalves, "Characterization of an oncofetal Chondroitin Sulfate epitope in Cancer". Universidade do Minho, M.Sc. thesis, p. 28 (2017).
8. Hamilton, Andrew, "Determination of the Structural Requirements for Modification of Vascular Endothelial Growth Factor Angiogenic Activity by Heparan Sulfate Oligosaccharides". University of Manchester, Ph.D. dissertation, pp. 66, 216 (2011).
9. Fessel, Gion, "Mechanics of collagen cross-links in tendon aging, disease and as potential treatment for injuries". ETH Zürich, Dr. sc. dissertation, pp. 114, 128 (2014).
10. Chang, Patrick S., "Physical regulation of cell surface access and cell adhesion by membrane-anchored hyaluronan". Georgia Institute of Technology, Ph.D. dissertation, pp. 40, 111 (2016).
11. Murienne, Barbara J., "Glycosaminoglycan contribution to the structure-mechanical properties of the posterior sclera". Johns Hopkins University, Ph.D. dissertation, pp. 68, 106, 114 (2016).
12. Tao, Chenqi, "Cell surface proteoglycans control astrocyte migration and retinal angiogenesis by regulating basement membrane assembly". Indiana University, Ph.D. dissertation, p. 26 (2016).
13. Fang, Fei, "Composition-Dependent Mechanisms of Multiscale Tendon Mechanics". Washington University in St. Louis, Ph.D. dissertation, p. 102 (2017).
14. Racine, Holly Lyn, "Targeted Limb Heating Augments the Actions of IGF1 in the Growth Plate and Increases Bone Elongation in Growing Mice". Marshall University, Ph.D. dissertation, p. 68 (2018).
15. Zhuola, "Ultrastructure and Mechanical changes in multi-scale of Sclera following Proteoglycan Depletion". University of Liverpool, Ph.D. dissertation, pp. 54, 76 (2018).
16. Mang, Tanja, "Evaluation of the therapeutic potential of GDF5 mutants to treat osteoarthritis". Technischen Universität Darmstadt, Dr. rer. nat. dissertation, pp. 38, 68 (2018).
17. Koch, Christopher D., "Proteoglycan dysregulation in thoracic aortic aneurysm and dissection". Cleveland State University, Ph.D. dissertation, pp. 40, 67 (2019).
18. Dong, Yan, "Investigation of TSG-6 as a potential biomarker and therapeutic target in osteoarthritis". University of Manchester, Ph.D. dissertation, p. 37 (2020).
19. Kanyo, N. *et al.*, *Sci. Rep.*, **10(1)**, 22422 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
C2905dat Rev 04/22 RBG,EM,GCY,SBC,MAM

MERCK